Vexim
Balma
About Vexim
VEXIM specializes in the development and sale of vertebral compression fracture (VCF) solutions. The company's flagship product is the SpineJack® system, a mechanical expandable VCF implant for fracture reduction and stabilization. The VEXIM portfolio is highly complementary to the Interventional Spine (IVS) business of Stryker's Instruments division whose key products include an extensive and innovative portfolio for vertebral augmentation, vertebroplasty, and radiofrequency ablation procedures, along with a diagnostic tool and decompression treatment advances for contained disc herniations. Vexim was created in February 2006 and is headquartered in Balma, France.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $17.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2015)
- Ticker: epa:ALVXM
- Website: fr.vexim.com
- Phone: +33 5 61 48 86 63
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/vexim-2005763 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.